# Temsirolimus in Myelodysplastic Syndrome (MDS)

> **NCT01111448** · PHASE2 · TERMINATED · sponsor: **Technische Universität Dresden** · enrollment: 20 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01111448
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2013-06
- **Final completion:** 2014-06
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Unfavourable Risk-Benefit-Ratio
- **Last updated:** 2015-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111448, "Temsirolimus in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01111448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*